ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,406,691 | -40.4% | 893,668 | -23.5% | 0.12% | -29.9% |
| Q2 2023 | $9,067,312 | +15.7% | 1,168,468 | -15.0% | 0.16% | +6.5% |
| Q1 2023 | $7,834,468 | -17.3% | 1,374,468 | -14.5% | 0.15% | -14.9% |
| Q4 2022 | $9,468,576 | +41.7% | 1,607,568 | -23.0% | 0.18% | +46.0% |
| Q3 2022 | $6,680,000 | -28.6% | 2,087,568 | 0.0% | 0.12% | -26.6% |
| Q2 2022 | $9,352,000 | -16.1% | 2,087,568 | 0.0% | 0.17% | -6.6% |
| Q1 2022 | $11,148,000 | -67.6% | 2,087,568 | -10.7% | 0.18% | -59.0% |
| Q4 2021 | $34,362,000 | -29.7% | 2,337,574 | 0.0% | 0.44% | -17.7% |
| Q3 2021 | $48,879,000 | +18.2% | 2,337,574 | 0.0% | 0.54% | +28.5% |
| Q2 2021 | $41,352,000 | -27.8% | 2,337,574 | 0.0% | 0.42% | -21.9% |
| Q1 2021 | $57,271,000 | -42.1% | 2,337,574 | -20.0% | 0.54% | -38.2% |
| Q4 2020 | $98,909,000 | +35.3% | 2,921,967 | 0.0% | 0.86% | -5.9% |
| Q3 2020 | $73,078,000 | -25.9% | 2,921,967 | 0.0% | 0.92% | -33.8% |
| Q2 2020 | $98,558,000 | – | 2,921,967 | – | 1.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $116,820,000 | 11.19% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $14,756,000 | 9.10% |
| Euclidean Capital LLC | 996,734 | $24,420,000 | 8.17% |
| Invus Financial Advisors, LLC | 1,007,575 | $24,686,000 | 5.66% |
| EcoR1 Capital, LLC | 3,092,218 | $75,759,000 | 3.36% |
| Ally Bridge Group (NY) LLC | 413,061 | $10,120,000 | 1.94% |
| EMERALD ADVISERS, LLC | 615,511 | $15,080,000 | 0.54% |
| Orbimed Advisors | 2,337,574 | $57,271,000 | 0.54% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 624,210 | $15,293,000 | 0.51% |
| Casdin Capital, LLC | 601,515 | $14,737,000 | 0.44% |